Our Research Center, with Crestovo (a pharmaceutical company), is seeking volunteers to participate in a clinical research study to prevent recurrent Clostridium difficile (C. difficile).
To be eligible for the study, you must be:
All Study visits will be performed and Investigational medication and procedures will be provided at no charge to you.
This trial is conducted under a US Food and Drug Administration Investigational New Drug Application.
Why is the ECOSPOR III study Important?
The leading risk factor for Clostridium difficile infection (CDI) is a prior history of taking antibiotics. Exposure to antibiotics can harm the good bacteria in the gut that make up our microbiome. These beneficial bacteria protect us from harmful invaders, like C. difficile, which can cause diarrhea. Although CDI treatment is available, many patients continue to have recurrent infections because their microbiome doesn't recover.
To qualify for this study, a person must:
All study-related visits, tests, and medication will be provided to participants at no cost. Reimbursement for time and travel may be provided.
If you have Crohn's consider taking part in the Etro Study.
WHY PARTICIPATE IN A CLINCIAL TRIAL?
You may get expert medical care from leading specialists and nurses throughout the study
You remain in control of your level of participation
You contribute to scientific understanding of Crohn's
Help us open the door to a potential new treatment option for patients with Crohn's disease.
If you have Crohn's disease, you may be able to join a new research study. Will you help us?
Are you living with Crohn's disease (CD)? We are looking for patients with CD to take part in a research study caaled VOLTAIRE-CD. The VOLTAIRE Study is looking at how safe and effective an investigational medication is when given to patients with CD.
You may be able to take part in this study if you, at a minimun:
* are 18-80 years of age
* were diagnosed more than 4 months ago with moderate to severe CD and still sometimes have flares.
Please contact us if you think you may be able to take part in, or if you are interested in learning more about, the VOLTAIRE-CD Study. We will be happy to answer any questions that you may have.
Do you still have symptoms after receiving treatment?
We are looking for people to help us evaluate the safety and effectiveness of a potential new treatment option for patients with Crohn's.
You may be eligible to take part if you:
The REVOLVE Study may last for up to 15 months and will require visits to the study center every 4 weeks. You will be monitored carefully by a team of doctors and nurses.
All study-related medications and assessments will be provided at no cost to you.
Want to know more?
If you are interested in taking part in the REVOLVE Study or would like more information, please contact:
How's your liver?
A potentially life-saving question you've probably never asked yourself.
NASH is a common but often 'silent' liver disease that ultimately leads to devastating consequences for many. Although similar to alcoholic liver diesease, it is not caused by drinking too much alcohol.
Both NASH and NAFLD are becoming more common, possibly because of the greater number of Americans with obesity. In the past 10 years, the rate of obesity has doubled in adults and tripled in children. Obesity also contributes to diabetes and high blood cholesterol, which can further complicate the health of someone with NASH. Diabetes and high blood cholesterol are also becoming more common among Americans (NIH, May2014).
YOU MAY QUALIFY IF:
Do you have Chronic Pancreatitis?
If you are eligible for this study, you will recieve the following at no cost to yourself: